FUJIFILM confirms £400 million investment to create the largest biopharmaceutical manufacturing site in the UK

FUJIFILM Diosynth Biotechnologies has confirmed a £400 million planned investment package at its UK facility in Billingham, Teesside. This investment package more than doubles the site’s existing development and manufacturing footprint, creating the largest multi-modal biopharmaceutical manufacturing site in the UK and is expected to create up to 350 highly-skilled jobs.

Sixfold Bioscience completes $10.5M USD (£7.8M GBP) seed financing

Investors include Y Combinator, Cantos Ventures, Lombard Street, Pi Campus and Angel investors, and non-dilutive funding has also been contributed by Innovate UK and the European Commission. Funding will support the advancement of Sixfold’s Mergo RNA therapeutics delivery platform, enabling delivery of mRNA and siRNA to tissues beyond the liver

BIA reacts to £400m investment in the UK by Fujifilm Diosynth Biotechnologies

Reacting to news that Fujifilm Diosynth Biotechnologies will be investing £400m into their UK manufacturing operation Steve Bates OBE, Chief Executive of the Bioindustry Association said

The BioIndustry Association and Kidney Research UK announce new 2022 Charity of the Year partnership

The BioIndustry Association (BIA) is delighted to announce Kidney Research UK as its charity partner for 2022. Kidney disease affects three million people in the UK with 20 people developing kidney failure each day. The charity undertakes research to end kidney disease, offering kidney patients and their families hope for the future. The partnership aims to raise funds, increase awareness of kidney health, and promote kidney research to the life sciences ecosystem.

Ensuring patient access to cell and gene therapies: The case for an innovative payment model

The BioIndustry Association (BIA) has today launched Ensuring patient access to cell and gene therapies: The case for an innovative payment model. The report, which has been produced with the support of the BIA’s Cell and Gene Therapy Advisory Committee, explores the potential benefits of cell and gene therapies for patients, the challenges they face in the current system and some of the solutions being explored in other countries.

Quell raises $156 million in Series B financing to advance its pioneering T-regulatory cell therapy pipeline and platform

Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focused investors. Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platform and manufacturing footprint

CEO Update | 29 November 2021

I’m delighted to finally be able to leave the house today after my period of isolation after a positive COVID-19 test. It was such a shame not to be able to join our bioprocessing community last week for the 18th annual bioProcess UK conference but I have been enjoying looking at the photos from this great event. News over the weekend of the Omnicron variant has led to the postponement of the WTO Ministerial meeting in Geneva where waivers on the IP of COVID-19 vaccines were to be discussed, so I’m no longer expecting to see global policy set in Geneva this week.

Altasciences Expands Ligand Binding Laboratory To Meet High Demand For Bioanalytical Solutions

Altasciences is pleased to announce the completion of a second expansion of our bioanalytical laboratory, which provides a cutting-edge research facility with new state-of-the-art equipment for ligand binding assays, and greater capacity for all our clients' needs.

How science prepares us for pandemic challenges

Antimicrobial resistance is a disaster waiting to happen, we must build our arsenal to combat it.

Guest blog: State of the UK cell and gene therapy industry in 2021

Despite the pandemic the cell and gene therapy industry in the UK has had another year of significant growth. The Cell and Gene Therapy Catapult has assessed the UK landscape in terms of investment, jobs and manufacturing capabilities and space. The organisation has published two 2021 reports, one focused on skills demand and one on GMP manufacturing.